Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2022.
-
Busy address KBO
42 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
FRI-PHARMA from Tongeren-Borgloon, company number BE0866926117, closed financial year 2025 with a result of € 239,063 after tax. For that financial year FRI-PHARMA recorded a gross margin of € -71,970 and equity of € 6.3 million. Compared with financial year 2024, the result moved from € 418,362 to € 239,063. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 6.3 million
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 239,063
▼ 43% vs 2024
Profit after tax over the fiscal year.
€ 78,539
▼ 50% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 5.9 million.
People and assets in 2025
€ 269
▼ € 544,739 vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 35,000
▲ 255% vs 2024
Loans from banks and other lenders, long and short.
€ 433,085
▲ 48% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 8,478,666 | € 1,590,112 | € 819,219 | € -71,970 | ▼ € 891,189 |
| Profit after taxes | € 4,981,979 | € 905,282 | € 418,362 | € 239,063 | ▼ 43% |
| Equity | € 4,733,195 | € 5,638,477 | € 6,056,838 | € 6,295,902 | ▲ 4% |
| Total debts | € 3,780,667 | € 2,145,123 | € 348,495 | € 468,085 | ▲ 34% |
| Cash | € 1,876,024 | € 1,410,038 | € 157,942 | € 78,539 | ▼ 50% |
| Retained profit | € 4,355,425 | € 5,260,707 | € 5,679,068 | € 5,918,132 | ▲ 4% |
| Dividend | € 1,615,392 | € 0 | € 0 | € 0 | |
| Bank debt | € 103,342 | € 30,120 | € 9,850 | € 35,000 | ▲ 255% |
| Balance sheet total | € 9,953,079 | € 9,222,816 | € 7,844,550 | € 8,203,203 | ▲ 5% |
| Employees (FTE) | 8 | 8 | 5.4 | - |
Key figures of FRI-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FRI-PHARMA?
What happened at FRI-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- YWAG Lux S.à.r.l. BO stepped down as director. NBB
- ALFA ADVISORY S.à.r.l. BO stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 239,063 (▼ 43% vs 2024). Source: NBB ↗
- YWAG Lux S.à.r.l. BO became a director. NBB
- ALFA ADVISORY S.à.r.l. BO became a director. NBB
- New establishment in Gembloux. KBO
- New establishment in Tongeren-Borgloon. KBO
- Start of the company according to the CBE. KBO
In short
From € 5 million profit in 2022 to € 239,063 profit in 2025.
Paid € 632,704 in corporate taxes since 2022.
Best year ever: 2022, with € 5 million profit.
On average € 151,700 of value added per employee in 2024.
A new publication or filing at FRI-PHARMA? We notify you, reason included.
Follow FRI-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of WEERTS LOGISTICS PARKS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FRI-PHARMAThe shares are held by WEERTS LOGISTICS PARKS (100%).
Directors
According to the 2025 annual accounts
YWAG Lux S.à.r.l. BO
Managing director · represented by YVES WEERTS
Also active at: Weerts Logistic Park XXXII, LAURA COAL BELGIUM, Weerts Logistic Park XXXI, Weerts Logistic Park III, Weerts Logistic Park IV, WEERTS LOGISTIC PARK VII, WEERTS LOGISTIC PARK VIII, WEERTS LOGISTIC PARK CV +28 more
since 2024 · until 2030
ALFA ADVISORY S.à.r.l. BO
Managing director · represented by ALAIN MEUNIER
Also active at: Weerts Logistic Park XXXII, LAURA COAL BELGIUM, Weerts Logistic Park XXXI, Weerts Logistic Park III, Weerts Logistic Park IV, WEERTS LOGISTIC PARK VII, WEERTS LOGISTIC PARK VIII, WEERTS LOGISTIC PARK CV +28 more
since 2024 · until 2030
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Heersterveldweg 11
3700 Tongeren-Borgloon
Rue Camille Hubert,Isnes 22
5032 Gembloux
Active since 1 April 2010
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 42 companies are registered at this address.
All companies at this address →Weerts Logistic Park XXXII same network
€ -44,715 gross margin · 2025
LAURA COAL BELGIUM same network
€ 1.2 million gross margin · 2025
WEERTS SUPPLY CHAIN
€ 67.4 million revenue · 2025
Weerts Logistic Park XXXI same network
€ -308,220 gross margin · 2025
Suites Life
€ 0 revenue · 2025
+37 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0866.926.117
- VAT number
- BE 0866.926.117
- Registered office
- Heersterveldweg 11, 3700 Tongeren-Borgloon
- Names & denominations
- FRI-PHARMA · WLP XIII (A)
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 August 2004
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Opslag
Opslag in koelpakhuizen
Overige opslag